Steve Frost
Urology · Dallas, TXNPI 1497794663
Payments from drug & device makers
Across 232 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$814
- Johnson & Johnson$438
- Bayer$268
- Boston Scientific$260
- Dendreon Pharmaceuticals LLC$235
- Blue Earth Diagnostics$204
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,04295%
- Education$2285%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 53 | $814 |
| Johnson & Johnson(3 entities) | 29 | $438 |
| Bayer | 13 | $268 |
| Boston Scientific | 13 | $260 |
| Dendreon Pharmaceuticals LLC | 15 | $235 |
| Blue Earth Diagnostics | 11 | $204 |
| AbbVie(2 entities) | 9 | $195 |
| Endo Pharmaceuticals Inc. | 9 | $160 |
| Sun Pharmaceutical Industries Inc. | 5 | $140 |
| Urogen Pharma, Inc. | 4 | $125 |
| Sumitomo Pharma America, Inc. | 5 | $107 |
| Pfizer | 5 | $99 |
| Travere Therapeutics, Inc. | 4 | $89 |
| Myovant Sciences Inc. | 4 | $88 |
| Urovant Sciences Inc | 5 | $87 |
| Antares Pharma, Inc. | 5 | $75 |
| Novartis | 4 | $74 |
| Ferring Pharmaceuticals Inc. | 5 | $73 |
| Amgen | 3 | $71 |
| Tolmar Pharmaceuticals, Inc. | 2 | $66 |
| Coloplast | 4 | $64 |
| Agiliti Surgical, Inc. | 1 | $64 |
| Foundation Medicine, Inc. | 3 | $59 |
| Biotissue Holdings Inc. | 2 | $54 |
| Mallinckrodt Enterprises LLC | 3 | $51 |
| Axonics, Inc. | 2 | $46 |
| Progenics Pharmaceuticals, Inc. | 2 | $42 |
| Merck | 1 | $31 |
| Medtronic | 2 | $29 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Laborie Medical Technologies Corp. | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Metuchen Pharmaceuticals | 1 | $17 |
| Neotract Inc. | 1 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Teleflex LLC | 1 | $13 |
| Cook Medical LLC | 1 | $12 |
How this compares
$4,270 in reported general payments places this provider in the 50th percentile of 878 urology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 21 | $214,216 |
| MyrbetriqMirabegron | 25 | $13,991 |
| Tamsulosin Hcl | 122 | $1,850 |
| Finasteride | 42 | $522 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 11 | $363 |
| Dutasteride | 11 | $229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $814 | $228,20646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 878 urology providers in Texas.
Other urology in Dallas
- Homa PorterDallas$1.8M
- Vitaly MargulisDallas$1.8M
- Solomon WolduDallas$1.2M
- James CochranDallas$1.1M
- Yair LotanDallas$1.1M
- Allen MoreyDallas$1M
- Claus RoehrbornDallas$292K
- Brett JohnsonDallas$175K
- Pat FulghamDallas$174K
- Gregory ThoresonDallas$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.